ClinicalTrials.gg
RecruitingNCT06701656Updated Jul 31, 2026

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

A Phase 2 interventional study of Cohort C: bevacizumab and Cohort C: placebo in Acute Respiratory Distress Syndrome (ARDS), ARDS and ARDS (Acute Respiratory Distress Syndrome), sponsored by PPD Development, LP. Recruiting at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by PPD Development, LP · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.

Planned enrollment
61st of 250
200 · median 52
Started
2025
with 13 others
Phase 2
74 of 324
8 open now
Primary completion
2028-07
later than 35 of 55 live
Registered
300th of 324
by date

Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 61st largest by planned enrollment of the 250 interventional ones that give a count, is one of 14 that started in 2025, is one of 74 in phase 2, reaches primary completion later than 35 of the 55 other live ones, and was the 300th registered.

Respiratory Distress Syndrome

1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 282 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Respiratory Distress Syndrome studies recruiting now, 117 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 324 studies in Respiratory Distress Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design.

Cohort C: Participants will be randomized to receive either a placebo or bevacizumab.

This record describes the default procedures and analyses for Cohort C. Please see NCT06703073 for information on the BP-ARDS-P2-001 Master Protocol.

Read the detailed description

This is a master protocol for a Phase 2 platform clinical trial to evaluate host-directed therapeutic candidates (i.e., investigational product, IP) for the treatment of hospitalized participants diagnosed with ARDS. The safety and efficacy of each IP will be studied within its own cohort (IP versus Placebo). All patients will continue to receive standard treatments for ARDS as per the investigator. An individual participant will complete the study in approximately 90 days. The study will include a screening period (\<24 hours from providing informed consent to treatment), in-hospital treatment period with IP/placebo starting on Day 1 through discharge from the hospital, and a follow-up period after discharge from the hospital through the end of study (Day 90 + 2 weeks). Outcome data will be assembled for each patient over time (such as ventilatory status, oxygenation, and survival). Functional status using the WHO Ordinal scale and Karnofsky scale will be collected. Resource utilization will be calculated (length of stay in a critical care setting, days intubated, and survival).

All participants will undergo a series of physical exams, laboratory assessments/biomarker collections, ECG, Chest X-ray or CT scan, and questionnaires through Day 90. Exploratory biomarkers will be evaluated over time to facilitate clinical learning. This record only includes information relevant to the bevacizumab cohort.

03

Conditions studied

  • Acute Respiratory Distress Syndrome (ARDS)
  • ARDS
  • ARDS (Acute Respiratory Distress Syndrome)
  • Acute Respiratory Distress Syndrome

Keywords

  • BARDA
  • JUST BREATHE
  • ARDS
  • Acute Respiratory Distress Syndrome
  • Acute Respiratory Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following inclusion criteria are in addition to the exclusion criteria specified in the Master Protocol NCT06703073.

  • ARDS Severity of mild, moderate or severe, based on PaO2/FiO2 or SpO2/FiO2 assessment at the time of randomization.

Exclusion criteria

Exclusion Criteria:

The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol NCT06703073.

  • Participant has a known allergy or to the active substance/, or Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies
  • Participant with established cirrhosis and a modified Score of 7 or greater
  • Participant was dialysis-dependent prior to hospitalization. Participant must have a urine dipstick for proteinuria \< 2+
  • The hospitalized participant has a history or currently experiencing the following:

    1. Participant must not have an (INR) >1.5 and/or aPTT >1.5 × (ULN) within 7 days prior to initiation of study treatment for participants not receiving anticoagulation. For participants on full dose oral or parenteral anticoagulants for therapeutic purposes the INR and/or activated partial thromboplastin time (aPTT) must be within therapeutic limits (according to institution standards) within 7 days prior to initiation of study treatment and the participant on a stable dose of anticoagulants for ≥ 2 weeks prior to initiation of study treatment.
    2. Participant with recent serious hemorrhage or history of recent hemoptysis > 2 episodes (defined as ≥2.5 mL of bright red blood per episode) within 1 month of screening.
    3. Participant with inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg). Antihypertensive therapy is permitted to achieve these parameters.
    4. Participant with a history of hypertensive crisis or hypertensive encephalopathy.
    5. Participant with a history of Grade ≥ 4 venous thromboembolisms.
    6. Participant with significant vascular disease (eg, aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 3 months of study drug treatment.
    7. Participant with history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, or active gastrointestinal bleeding within 6 months of study drug treatment.
    8. Participant with serious, non-healing wound, active ulcer, or untreated bone fracture.
    9. Participant with history or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (ie, in the absence of therapeutic anticoagulation).
    10. Participant with cardiovascular disease including cerebrovascular accident or myocardial infarction within previous 6 months, unstable angina, congestive heart failure, or serious cardiac arrhythmia uncontrolled by medication.
    11. Participant with a count of \<75×109/L.
    12. Participant with current or recent (\<10 days prior to initiation of study treatment) use of aspirin (>325 mg/day) or clopidogrel (>75 mg/day).
    13. Participant is receiving a direct anticoagulant (DOAC) such as dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) without the availability of a reversal agent at the site.
    14. Participant is receiving a DOAC such as betrixaban (Bevyxxa®) and edoxaban (Lixiana®) for which there is no approved reversal agent.
    15. Participant has urine dipstick for proteinuria ≥ 2+
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Cohort C: bevacizumab

    Drug: Cohort C: bevacizumab

  • Placebo comparator
    Cohort C: placebo

    Drug: Cohort C: placebo

Interventions

  • Administered as a single IV dose of 500 mg on Day 1

  • DrugCohort C: placebo

    Administered as a single IV dose of placebo on Day 1

06

What researchers measure

Primary outcomes

  1. All-cause mortality (ACM) rate at Day 28

    Time frame: Day 28

Secondary outcomes

  1. ACM at Day 60 and Day 90

    Time frame: Day 60 and Day 90

  2. ACM+ at Day 28, Day 60, and Day 90

    ACM+ composite score will be constructed by combining ACM and participant-relevant, infection-related Adverse Events (AE) and Serious Adverse Events (SAEs) from the MedDRA toxic/septic shock standardized MedDRA queries (SMQ).

    Time frame: Time Frame: Day 28, Day 60, and Day 90

  3. Improvements in oxygenation measured as change from baseline in PaO2/FiO2 ratio up to and including Day 28 (or discharge, whichever is earlier)

    Time frame: Up to and including Day 28 or until Discharge (whichever is earlier)

  4. Incidence of new invasive mechanical ventilation use during the study up to and including Day 28

    Time frame: Up to and including Day 28

  5. Ventilator-free days up to and including Day 28

    Time frame: Up to and including Day 28

  6. Proportion of participants alive and free of mechanical ventilation at Days 28, 60, and 90

    Time frame: Days 28, 60, and 90

  7. Time to recover gas exchange to a PaO2/FiO2 ≥ 300 measured on 2 consecutive days during the first 28 days after informed consent

    Time frame: Up to and including Day 28

  8. Extracorporeal Membrane Oxygenation (ECMO) free days up to and including Day 28

    Time frame: up to and including Day 28

  9. Incidence of participants with new ECMO use during the study up to and including Day 28.

    Time frame: up to and including Day 28

  10. Proportion of participants alive and free of ECMO at Days 28, 60, and 90

    Time frame: Days 28, 60, and 90

  11. Proportion of participants achieving a ≥2-point improvement from baseline in the World Health Organization (WHO) 8-levels ordinal scale (from 0-8)

    Time frame: While Hospitalized (up to 90 days)

  12. Time to an improvement of one category and two categories from baseline using the WHO 8-levels ordinal scale (from 0-8) at Days 28, 60, and 90 (while hospitalized)

    Time frame: While Hospitalized (up to 90 days)

  13. Mean change in the WHO 8-levels ordinal scale from baseline through Day 90 (while hospitalized)

    Time frame: While Hospitalized (up to 90 days)

  14. Proportion of participants who improve clinical status as measured by the Karnofsky scale

    The Karnofsky scale is used to assess the general condition of the patient. Scores range from 0 to 100 with higher scores indicating better functional ability.

    Time frame: Post hospitalization through Day 90

  15. Days of hospitalization up to and including Day 28

    Time frame: up to and including Day 28

  16. Days of ICU stay up to and including Day 28

    Time frame: up to and including Day 28

  17. Change in Short Form Health Survey (SF-12) from hospital discharge to Day 60 and to Day 90

    The SF-12 is a self-reported outcome measure composed by 12 items which examine eight dimensions of physical and mental health. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

    Time frame: from hospital discharge to Day 60 and to Day 90from hospital discharge to Day 60 and to Day 90

  18. Change in St. George's Respiratory Questionnaire (SGRQ) from hospital discharge to Day 60 and to Day 90

    The SGRQ comprises of 50 items and consists of two parts. The first part pertains to symptoms and the second pertains to functional status as well as social and psychological impact of disease. Overall scores range between 0 and 100 with higher scores indicating more limitations.

    Time frame: From hospital discharge to Day 60 and to Day 90

  19. Incidence and severity of adverse events (AEs) /adverse event of special interest (AESI) / serious adverse event (SAEs)

    Time frame: Through Day 90

07

Study locations

28 of 41 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jul 2028, 33 months after the start.

Of 59 phase 2 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 22, 2024
StartActual
Oct 28, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Sep 2028
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06701656
Lead sponsor
PPD Development, LP
Collaborators
Biomedical Advanced Research and Development Authority, InflaRx GmbH, Edesa Biotech Inc., Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Oct 28, 2025
Primary completion
Jul 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jul 31, 2026

Study contacts

Just Breathe Trial Team
Contact
crgjustbreathealerts.sm@thermofisher.com
Please email

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion